Skip to main content
NCBI home page
Indian Journal of Surgical Oncology logoLink to Indian Journal of Surgical Oncology
. 2010 Aug 7;1(1):59–67. doi: 10.1007/s13193-010-0013-y

Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study

Igor Langer 1,2, Ulrich Guller 3, Carsten T Viehl 2, Holger Moch 4, Edward Wight 5, Felix Harder 2, Daniel Oertli 2, Markus Zuber 6,✉
PMCID: PMC3420993  PMID: 22930620

Abstract

Objectives

To evaluate the long-term disease-free and overall survival of patients with sentinel lymph node (SLN) micrometastases, in whom a completion axillary lymph node dissection (ALND) was systematically omitted.

Background

The use of step sectioning and immunohistochemistry for SLN analysis results in a more accurate histopathologic examination and a higher detection rate of micrometastases. However, the clinical relevance and therapeutic implications of SLN micrometastases remain a matter of debate.

Methods

In this prospective study, 236 SLN biopsies were performed in 234 consecutive early-stage breast cancer patients (T1, T2 ≤ 3 cm, cN0 M0) between 1998 and 2002. The SLN were examined by step sectioning and stained with hematoxylin and eosin and immunohistochemistry. None of the patients with negative SLN or SLN micrometastases (International Union Against Cancer classification, >0.2 to ≤ 2 mm) underwent a completion ALND or radiation to the axilla. Long-term overall and disease-free survivals were compared between patients with negative SLN and those with SLN micrometastases by log rank tests.

Results

The SLN was negative in 55% of patients (123 of 224). SLN micrometastases were detected in 27 patients (27 of 224, 12%). After a median followup of 77 months (range, 24–106 months), neither locoregional recurrences nor distant metastases occurred in any of the 27 patients with SLN micrometastases. There were no statistically significant differences for overall (P = 0.656), locoregional (P = 0.174), and axillary and distant disease-free survival (P = 0.15) between patients with negative SLN and SLN micrometastases.

Conclusions

This analysis of unselected patients provides evidence that a completion level I and II ALND may be safely omitted in early-stage breast cancer patients with SLN micrometastases.

Footnotes

This article was originally published in Ann Surg Oncol (2009) 16:3366-3374 DOI 10.1245/s10434-009-0661-8 and is published here in its entirety.

References

  • 1.Giuliano A.E., Jones R.C., Brennan M., Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–2350. doi: 10.1200/JCO.1997.15.6.2345. [DOI] [PubMed] [Google Scholar]
  • 2.Schwartz G.F., Giuliano A.E., Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542–2551. doi: 10.1002/cncr.10539. [DOI] [PubMed] [Google Scholar]
  • 3.Langer I., Guller U., Berclaz G., et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245:452–461. doi: 10.1097/01.sla.0000245472.47748.ec. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lucci A., McCall L.M., Beitsch P.D., et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–2663. doi: 10.1200/JCO.2006.07.4062. [DOI] [PubMed] [Google Scholar]
  • 5.Mansel R.E., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. doi: 10.1093/jnci/djj158. [DOI] [PubMed] [Google Scholar]
  • 6.Chu K.U., Turner R.R., Hansen N.M., Brennan M.B., Giuliano A.E. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999;6:756–61. doi: 10.1007/s10434-999-0756-2. [DOI] [PubMed] [Google Scholar]
  • 7.Viale G., Maiorano E., Pruneri G., et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241:319–325. doi: 10.1097/01.sla.0000150255.30665.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Langer I., Marti W.R., Guller U., et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241:152–158. doi: 10.1097/01.sla.0000149305.23322.3c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Langer I., Zuber M., Kochli O.R., et al. [Validation study of the sentinel lymph node (SLN) method in invasive breast carcinoma. Personal data and review of the literature] Swiss Surg. 2000;6:128–136. doi: 10.1024/1023-9332.6.3.128. [DOI] [PubMed] [Google Scholar]
  • 10.Goldhirsch A., Glick J.H., Gelber R.D., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601–1608. doi: 10.1093/jnci/90.21.1601. [DOI] [PubMed] [Google Scholar]
  • 11.Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 2001;19:3817–3827. doi: 10.1200/JCO.2001.19.18.3817. [DOI] [PubMed] [Google Scholar]
  • 12.Veronesi U., Galimberti V., Mariani L., et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer. 2005;41:231–237. doi: 10.1016/j.ejca.2004.05.009. [DOI] [PubMed] [Google Scholar]
  • 13.Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–2559. doi: 10.1200/JCO.2000.18.13.2553. [DOI] [PubMed] [Google Scholar]
  • 14.Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinellymph-node resection and conventional axillary-lymphnode dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–888. doi: 10.1016/S1470-2045(07)70278-4. [DOI] [PubMed] [Google Scholar]
  • 15.Martin R.C., Chagpar A., Scoggins C.R., et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg. 2005;241:1005–1012. doi: 10.1097/01.sla.0000165200.32722.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bergkvist L., Frisell J. Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg. 2005;92:1221–1224. doi: 10.1002/bjs.5052. [DOI] [PubMed] [Google Scholar]
  • 17.Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553. doi: 10.1056/NEJMoa012782. [DOI] [PubMed] [Google Scholar]
  • 18.Shivers S., Cox C., Leight G., et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002;9:248–255. doi: 10.1007/BF02573062. [DOI] [PubMed] [Google Scholar]
  • 19.Tafra L., Lannin D.R., Swanson M.S., et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51–59. doi: 10.1097/00000658-200101000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Cody H.S., III, Hill A.D., Tran K.N., Brennan M.F., Borgen P.I. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg. 1999;229:723–726. doi: 10.1097/00000658-199905000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ploeg I.M., Nieweg O.E., Rijk M.C., Valdés Olmos R.A., Kroon B.B. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277–1284. doi: 10.1016/j.ejso.2008.01.034. [DOI] [PubMed] [Google Scholar]
  • 22.Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–2988. doi: 10.1073/pnas.0530291100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Colpaert C., Vermeulen P., Jeuris W., et al. Early distant relapse in ‘nodenegative’ breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol. 2001;193:442–449. doi: 10.1002/path.829. [DOI] [PubMed] [Google Scholar]
  • 24.Furukawa T., Kubota T., Tanino H., et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res. 2000;20:3657–3658. [PubMed] [Google Scholar]
  • 25.Hill A.D., Tran K.N., Akhurst T., et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999;229:528–535. doi: 10.1097/00000658-199904000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Reynolds C., Mick R., Donohue J.H., et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720–1726. doi: 10.1200/JCO.1999.17.6.1720. [DOI] [PubMed] [Google Scholar]
  • 27.Turner R.R., Chu K.U., Qi K., et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–581. doi: 10.1002/1097-0142(20000801)89:3<574::AID-CNCR12>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  • 28.Veronesi U., Paganelli G., Viale G., et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91:368–373. doi: 10.1093/jnci/91.4.368. [DOI] [PubMed] [Google Scholar]
  • 29.Veronesi U., Galimberti V., Zurrida S., et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer. 2001;37:454–458. doi: 10.1016/S0959-8049(00)00410-X. [DOI] [PubMed] [Google Scholar]
  • 30.Weaver D.L., Krag D.N., Ashikaga T., Harlow S.P., O’Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000;88:1099–107. doi: 10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  • 31.Rosen P.R., Groshen S., Saigo P.E., Kinne D.W., Hellman S. A longterm follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol. 1989;7:355–366. doi: 10.1200/JCO.1989.7.3.355. [DOI] [PubMed] [Google Scholar]
  • 32.Dowlatshahi K., Fan M., Snider H.C., Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer. 1997;80:1188–1197. doi: 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 33.Cote R.J., Peterson H.F., Chaiwun B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354:896–900. doi: 10.1016/S0140-6736(98)11104-2. [DOI] [PubMed] [Google Scholar]
  • 34.Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990;335:1565–1568. [PubMed] [Google Scholar]
  • 35.Colleoni M., Rotmensz N., Peruzzotti G., et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005;23:1379–1389. doi: 10.1200/JCO.2005.07.094. [DOI] [PubMed] [Google Scholar]
  • 36.Veronesi U., Paganelli G., Viale G., et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2006;7:983–990. doi: 10.1016/S1470-2045(06)70947-0. [DOI] [PubMed] [Google Scholar]
  • 37.Chagpar A., Middleton L.P., Sahin A.A., et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005;103:1581–1586. doi: 10.1002/cncr.20934. [DOI] [PubMed] [Google Scholar]
  • 38.Ganaraj A., Kuhn J.A., Jones R.C., et al. Predictors for nonsentinel node involvement in breast cancer patients with micrometastases in the sentinel lymph node. Proc (Bayl Univ Med Cent) 2003;16:3–6. doi: 10.1080/08998280.2003.11927881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Liang W.C., Sickle-Santanello B.J., Nims T.A. Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am J Surg. 2001;182:365–368. doi: 10.1016/S0002-9610(01)00738-3. [DOI] [PubMed] [Google Scholar]
  • 40.Fournier K., Schiller A., Perry R.R., Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg. 2004;239:859–863. doi: 10.1097/01.sla.0000128302.05898.a7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Schrenk P., Konstantiniuk P., Wolfl S., et al. Prediction of nonsentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg. 2005;92:707–713. doi: 10.1002/bjs.4937. [DOI] [PubMed] [Google Scholar]
  • 42.Guenther J.M., Hansen N.M., DiFronzo L.A., et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138:52–56. doi: 10.1001/archsurg.138.1.52. [DOI] [PubMed] [Google Scholar]
  • 43.Fant J.S., Grant M.D., Knox S.M., et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10:126–30. doi: 10.1245/ASO.2003.04.022. [DOI] [PubMed] [Google Scholar]
  • 44.Jeruss J.S., Winchester D.J., Sener S.F., et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12:34–40. doi: 10.1007/s10434-004-1164-2. [DOI] [PubMed] [Google Scholar]
  • 45.Naik A.M., Fey J., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–468. doi: 10.1097/01.sla.0000137130.23530.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Fan Y.G., Tan Y.Y., Wu C.T., et al. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Ann Surg Oncol. 2005;12:705–11. doi: 10.1245/ASO.2005.08.020. [DOI] [PubMed] [Google Scholar]
  • 47.Carlo J.T., Grant M.D., Knox S.M., et al. Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer. Proc (Bayl Univ Med Cent) 2005;18:103–107. doi: 10.1080/08998280.2005.11928044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Haid A., Knauer M., Koeberle-Wuehrer R., et al. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol. 2006;32:1180–1185. doi: 10.1016/j.ejso.2006.04.010. [DOI] [PubMed] [Google Scholar]
  • 49.Hwang R.F., Gonzalez-Angulo A.M., Buchholz T.A., et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–730. doi: 10.1002/cncr.22847. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Surgical Oncology are provided here courtesy of Springer

RESOURCES